Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Cardiovascular / Metabolism / Other Therapeutic Area by Year
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M) ($M)
Johnson & Johnson Cardiovascular / Metabolism / Other Therapeutic Area: $3,778M in FY2025, up 6.1% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 3,778 | +6.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 3,562 | -3.0% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 3,671 | -5.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 3,887 | -5.6% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 4,119 | -9.2% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 4,534 | -12.7% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 5,192 | -10.7% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 5,816 | -7.5% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 6,287 | -1.7% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 6,396 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up cardiovascular / Metabolism / Other Therapeutic Area
- Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. sales ($M)3,175 · FY2025
- Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International sales ($M)603 · FY2025
- Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide reported growth YoY (%)6.1% · FY2025
- Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)6.0% · FY2025
- XARELTO (rivaroxaban) — Worldwide sales ($M)2,633 · FY2025
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M)448 · FY2022
- PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — Worldwide sales ($M)479 · FY2021
- Other Cardiovascular / Metabolism / Other medicines — Worldwide sales ($M)1,145 · FY2025
Cite this data
StockData. (2026). Johnson & Johnson Cardiovascular / Metabolism / Other Therapeutic Area ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta-cvm
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.